Back to top
more

Neogen (NEOG)

(Real Time Quote from BATS)

$15.62 USD

15.62
289,276

+0.02 (0.13%)

Updated Oct 2, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate Neogen (NEOG) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Sweta Killa

Sector ETF report for PSCH

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Neogen (NEOG) Down 17.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Neogen (NEOG) Earnings Beat, Revenues Lag Estimates in Q1

by Zacks Equity Research

Accretive integrations and an expanding international footprint drive Neogen's (NEOG) earnings in Q1.

    Neogen (NEOG) Q1 Earnings Beat Estimates

    by Zacks Equity Research

    Neogen (NEOG) delivered earnings and revenue surprises of 3.57% and -3.71%, respectively, for the quarter ended August 2018. Do the numbers hold clues to what lies ahead for the stock?

      Neogen (NEOG) Q1 Earnings Preview: What's Shaping Up?

      by Zacks Equity Research

      Neogen (NEOG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        Neogen's Livestock Genetic Buyout Expands Animal Safety Suite

        by Zacks Equity Research

        The acquisition of Livestock Genetic will position Neogen (NEOG) as a leading agrigenomics company worldwide.

          Neogen's (NEOG) Listeria Right Now Gets Approval from AOAC

          by Zacks Equity Research

          Neogen's (NEOG) Listeria Right Now likely to prove beneficial in preventing food-borne diseases in the United States.

            Neogen (NEOG) Up 1.5% Since Earnings Report: Can It Continue?

            by Zacks Equity Research

            Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Neogen (NEOG) Earnings and Revenues Beat Estimates in Q4

              by Zacks Equity Research

              Neogen (NEOG) sticks to its four-pronged growth strategy for steady progress. Also, the company's accretive buyouts and its broader international base are a boon.

                Sweta Killa headshot

                Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

                by Sweta Killa

                Style Box ETF report for DWAS

                  Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

                  by Zacks Equity Research

                  Style Box ETF report for DWAS

                    Neogen (NEOG) Q3 Earnings Beat, Revenues Miss Estimates

                    by Zacks Equity Research

                    Neogen (NEOG) witnesses year-over-year revenue increase in both the segments in Q3.

                      Haemonetics (HAE) Hits a 52-Week High: What's Driving It?

                      by Zacks Equity Research

                      Haemonetics (HAE) gains from promising financial results in the third quarter of fiscal 2018.

                        Masimo's (MASI) Eve Gets CE Mark, Bolsters CCHD Diagnosis

                        by Zacks Equity Research

                        Masimo's (MASI) newborn screening application, Eve, will make CCHD diagnosis simple and cost effective.

                          Tirthankar Chakraborty headshot

                          5 Top Earnings Growth Stocks to Buy in February

                          by Tirthankar Chakraborty

                          We have shortlisted 5 top-rated stocks that have striking earnings growth and positive estimate revisions.

                            CVS Health Grows in PBM With Rheumatoid Arthritis Program

                            by Zacks Equity Research

                            The new Transform Rheumatoid Arthritis Care program to help CVS Health (CVS) provide a personalized whole-patient support through specialty pharmacy and embedded AccordantCare nurses.

                              Positive Market Trends Aid Cardiovascular Systems Amid Woes

                              by Zacks Equity Research

                              Cardiovascular Systems (CSII) firmly stands to gain from several favorable trends existing in the PAD and CAD market spaces.

                                BD's CE Mark and Check-Point's Screening Test to Fight CPO

                                by Zacks Equity Research

                                BD (BDX)-Check-Points' advanced bacterial screening assay will help lower mortality rates caused by AMR.

                                  DaVita (DVA) Partners with Epic to Launch EHR for Patients

                                  by Zacks Equity Research

                                  DaVita (DVA) collaborates with Epic to introduce electronic health record facility for patients, reduce costs and enhance healthcare.

                                    Can Neogen (NEOG) Stock Continue to Grow Earnings?

                                    by Zacks Equity Research

                                    Neogen (NEOG) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.

                                      Neogen (NEOG) Q2 Earnings Beat Estimates, Revenues Miss

                                      by Zacks Equity Research

                                      Neogen (NEOG) rides high on balanced growth across all business segments in Q2.

                                        Neogen (NEOG) Earnings and Revenues Beat Estimates in Q1

                                        by Zacks Equity Research

                                        Neogen (NEOG) rides high on balanced growth across all business segments.

                                          Neogen Introduces Test for Listeria in Environmental Samples

                                          by Zacks Equity Research

                                          Neogen Corporation (NEOG) recently developed Listeria Right Now test system.